Letter by Kurnik et al Regarding Article, “Antithrombotic Therapy and Bleeding Risk in a Prospective Cohort Study of Patients With Cerebral Cavernous Malformations” | Zendy

Yvonne Schwammenthal | Zendy; David Tanné | Zendy; Daniel Kurnik | Zendy

Open Access

Letter by Kurnik et al Regarding Article, “Antithrombotic Therapy and Bleeding Risk in a Prospective Cohort Study of Patients With Cerebral Cavernous Malformations”

Author(s) -

Yvonne Schwammenthal,

David Tanné,

Daniel Kurnik

Publication year - 2013

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.111.000806

Subject(s) - medicine , antithrombotic , cavernous malformations , prospective cohort study , cohort , cohort study , stroke (engine) , surgery , pediatrics , lesion , mechanical engineering , engineering

To the Editor:In their prospective cohort study of 87 patients with cerebral cavernous malformations (CCMs), Schneble et al1 observed 11 CCM-related bleeds in 9 patients without antithrombotic treatments, whereas there was no bleeding event in 16 patients on antithrombotic treatment. For their analyses, the authors grouped together patients using antiplatelet drugs (n=11) and warfarin (n=5), although these drugs are associated with substantially different risks of intracranial bleeding in the general population, and although the 5 patients on warfarin (31% of the subgroup receiving antithrombotic therapy) contributed disproportionally to patient-years (68%) and lesion-years …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research